Posted by Michael Wonder on 05 Aug 2015
Bayerâs Adempas (riociguat) approved for the treatment of two life-threatening forms of pulmonary hypertension in the EU
31 March 2014 -
Bayer today announced that Adempas (riociguat) has been approved by the European Commission for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Adempas is indicated for the treatment of adult patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent or recurrent CTEPH after surgical treatment, and for the treatment of adult patients with pulmonary arterial hypertension (PAH) as a monotherapy or in combination with endothelin receptor antagonists. Adempas is a soluble guanylate cyclase (sGC) stimulator, and the first member of a novel class of compounds. Adempas is the first and only drug treatment approved for patients with CTEPH.
For more details, go to: http://www.news.bayer.com/baynews/baynews.nsf/id/A4BA7EA8C0F95E3EC1257CAC002B1789
Posted by:
Michael Wonder
Posted in:
